Literature DB >> 26851962

Comparison of Long-Term Mortality for Cardiac Diseases in Patients With Versus Without Diabetes Mellitus.

Alberto Cordero1, Ramón López-Palop2, Pilar Carrillo2, Jose Moreno-Arribas2, Vicente Bertomeu-González2, Araceli Frutos2, María García-Carrilero2, Clara Gunturiz2, Vicente Bertomeu-Martínez2.   

Abstract

Diabetes mellitus confers the highest mortality risk in primary and secondary cardiovascular prevention, but long-term prognosis differences between different forms of cardiovascular disease have not been assessed. We hypothesized that acute heart failure (HF) could have poorer outcomes than acute coronary heart disease (CHD) in patients with diabetes. We performed a prospective study of all consecutive patients admitted in a single year. Patients were categorized according to main cardiologic diagnosis: acute HF, acute CHD, rhythm disorders, or noncardiac disease. A total of 1,293 patients were included, 31.8% had diabetes and had higher mean age, more risk factors, previous cardiovascular disease, and co-morbidities. Hospital mortality (5.6% vs 1.7%; p <0.01) was higher in patients with diabetes. During follow-up (median 58.0 months; interquartile range 31.0 to 60.0), diabetic patients had higher cardiovascular mortality (27.2% vs 9.6%; p <0.01) and all-cause mortality (35.8% vs 14.5%; p <0.01); cardiovascular disease accounted for 75% of deaths. According to discharge diagnosis, patients with diabetes only had higher mortality rates in the subgroup of acute CHD. Acute HF was the diagnosis with higher cardiovascular (36.9%) and all-cause mortality (44.1%), followed by acute CHD (16.8% and 24.4%) and rhythm disorders (5.8% and 8.8%). Multivariate analysis identified an independent association with higher long-term mortality of acute HF and acute CHD in patients with and without diabetes. In conclusion, 1/3 of cardiology-admitted patients have diabetes and have poorer long-term prognosis, especially when discharged with the diagnosis of acute HF or acute CHD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26851962     DOI: 10.1016/j.amjcard.2015.12.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Diabetes mellitus, revascularization and outcomes in elderly patients with myocardial infarction-related cardiogenic shock.

Authors:  Miquel Gual; Ariza Albert-Solé; Marí Garcaí Maárquez; Cristina Fernández; José L Bernal; Francesc Formiga; María-Isabel Barrionuevo; José C Sánchez-Salado; Victòria Lorente; Júlia Pascual; Isaac Llaó; Oriol Alegre; Angel Cequier; Javier Elola
Journal:  J Geriatr Cardiol       Date:  2020-10-28       Impact factor: 3.327

2.  The Effects of Synbiotic Supplementation on Carotid Intima-Media Thickness, Biomarkers of Inflammation, and Oxidative Stress in People with Overweight, Diabetes, and Coronary Heart Disease: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Alireza Farrokhian; Fariba Raygan; Ali Soltani; Maryam Tajabadi-Ebrahimi; Mehran Sharifi Esfahani; Ali Akbar Karami; Zatollah Asemi
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

3.  Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.

Authors:  Kamel Mohammedi; Mark Woodward; Michel Marre; Stephen Colagiuri; Mark Cooper; Stephen Harrap; Giuseppe Mancia; Neil Poulter; Bryan Williams; Sophia Zoungas; John Chalmers
Journal:  Cardiovasc Diabetol       Date:  2017-07-27       Impact factor: 9.951

4.  Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome.

Authors:  Aurora Baluja; Moisés Rodríguez-Mañero; Alberto Cordero; Bahij Kreidieh; Diego Iglesias-Alvarez; Jose M García-Acuña; Alvaro Martínez-Gómez; Rosa Agra-Bermejo; Leyre Alvarez-Rodríguez; Charigan Abou-Jokh; Mónica López-Ratón; Francisco Gude-Sampedro; Julián Alvarez-Escudero; Jose R González-Juanatey
Journal:  Diab Vasc Dis Res       Date:  2019-12-16       Impact factor: 3.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.